

Margherita Rimini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9598009/publications.pdf>

Version: 2024-02-01

14
papers

200
citations

1305906

8
h-index

1255698

13
g-index

15
all docs

15
docs citations

15
times ranked

145
citing authors

#	ARTICLE	IF	CITATIONS
1	Why does survival of hepatocellular carcinoma patients remain so low? Key stumbling blocks and questions in preclinical and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 483-494.	1.9	2
2	Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. <i>Journal of Chemotherapy</i> , 2022, 34, 543-549.	0.7	1
3	Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. <i>European Journal of Cancer</i> , 2022, 171, 232-241.	1.3	7
4	Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00286.	1.3	15
5	Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. <i>Liver International</i> , 2021, 41, 1389-1397.	1.9	45
6	Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3665-3671.	1.2	12
7	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib. <i>Hepatology Research</i> , 2021, 51, 796-802.	1.8	4
8	Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. <i>Hpb</i> , 2021, 23, 915-920.	0.1	14
9	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2021, 41, 2997-3008.	1.9	18
10	Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. <i>Hepatology Research</i> , 2021, 51, 1229-1241.	1.8	33
11	Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. <i>Targeted Oncology</i> , 2021, 16, 653-661.	1.7	0
12	Cholangiocarcinoma: new perspectives for new horizons. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1367-1383.	1.4	13
13	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. <i>Cancer Management and Research</i> , 2021, Volume 13, 9379-9389.	0.9	31
14	Child Pugh and ALBI grade: past, present or future?. <i>Annals of Translational Medicine</i> , 2020, 8, 1044-1044.	0.7	5